ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma—final results of a phase I/IIa study

Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander
Department of Hematology/Oncology, Division of Blood and Marrow Transplant and Cellular Therapy, OhioHealth, Columbus, OH, USA and OhioHealth, Columbus, OH
Department of Hematooncology, University Hospital Ostrava, Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
Všeobecná fakultní nemocnice, Prague, Czech Republic
Fourth Department of Medicine - Hematology, Charles University Hospital, Hradec Králové, Czech Republic
Hôpital Morvan, Brest
Department of Hematology, Centre Hospitalier Lyon-Sud, University Claude Bernard Lyon 1, Pierre-Bénite
Hospital Clinico Universitario de Salamanca/IBSAL/CIC, Salamanca
Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona
Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Oncopeptides AB, Stockholm
Oncopeptides AB, Stockholm
Oncopeptides AB, Stockholm
Fakultní nemocnice Brno, Brno, Czech Republic
Haematologica Early view Aug 31, 2023